0.05%
8.93%
-3.37%
0.32%
16.67%
17.90%
36.91%
AI Spotlight on INVA
Company Description
Innoviva, Inc.engages in the development and commercialization of pharmaceuticals in the United States and internationally.Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
Innoviva, Inc.has a strategic partnership with Sarissa Capital Management LP.The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc.and changed its name to Innoviva, Inc.in January 2016.
Innoviva, Inc.was incorporated in 1996 and is headquartered in Burlingame, California.
Market Data
| Last Price | 18.9 |
| Change Percentage | 0.05% |
| Open | 18.94 |
| Previous Close | 18.89 |
| Market Cap ( Millions) | 1183 |
| Volume | 339651 |
| Year High | 21.28 |
| Year Low | 14.33 |
| M A 50 | 18.42 |
| M A 200 | 17.89 |
Financial Ratios
| FCF Yield | 13.72% |
| Dividend Yield | 0.00% |
| ROE | 9.52% |
| Debt / Equity | 38.29% |
| Net Debt / EBIDTA | -4.59% |
| Price To Book | 1.77 |
| Price Earnings Ratio | 18.31 |
| Price To FCF | 7.29 |
| Price To sales | 3.26 |
| EV / EBITDA | 11.62 |
News
- Dec -16 - Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
- Oct -15 - Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024
- Jul -09 - The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
- Jun -27 - 3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
- Jun -18 - Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
- Jun -03 - Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- May -31 - 3 Under-$20 Stocks That Could Make You a Fortune
- May -20 - Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
- May -20 - Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
- May -08 - Innoviva to Participate in the BofA Securities Health Care Conference
- Apr -24 - Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
- Mar -04 - Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
- Jan -10 - If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
- Nov -01 - Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Nov -01 - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
- Oct -27 - Is Phillips 66 (PSX) Stock Undervalued Right Now?
- Oct -09 - Innoviva: A Lot Of Moving Parts
- Sep -18 - XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
- Aug -25 - Innoviva Appoints Stephen Basso as Chief Financial Officer
- Jul -13 - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Respiratory Products
Expected Growth : 8 %
What the company do ?
Innoviva, Inc.'s Respiratory Products segment focuses on developing and commercializing innovative therapies for respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
Why we expect these perspectives ?
Innoviva's Respiratory Products segment growth is driven by increasing adoption of its inhalation therapy products, strong demand for COPD and asthma treatments, and strategic partnerships. Additionally, expanding product portfolio, geographic reach, and growing awareness of respiratory diseases contribute to the 8% growth rate.
Innoviva, Inc. Products
| Product Range | What is it ? |
|---|---|
| Breo Ellipta | A once-daily, inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) combination product for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). |
| Anoro Ellipta | A once-daily, inhaled long-acting muscarinic antagonist/long-acting beta2-adrenergic agonist (LAMA/LABA) combination product for the long-term, maintenance treatment of airflow obstruction in patients with COPD. |
| Trelegy Ellipta | A once-daily, inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta2-adrenergic agonist (ICS/LAMA/LABA) triple-combination product for the long-term, maintenance treatment of airflow obstruction in patients with COPD. |
Innoviva, Inc.'s Porter Forces
Threat Of Substitutes
Innoviva, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for chronic obstructive pulmonary disease (COPD) and asthma.
Bargaining Power Of Customers
Innoviva, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the presence of a small number of large pharmacy benefit managers.
Bargaining Power Of Suppliers
Innoviva, Inc. has a moderate bargaining power of suppliers due to the presence of a few large suppliers of raw materials and the company's dependence on these suppliers.
Threat Of New Entrants
Innoviva, Inc. has a high threat of new entrants due to the attractiveness of the respiratory disease market and the presence of several large pharmaceutical companies with the resources to enter the market.
Intensity Of Rivalry
Innoviva, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 39.86% |
| Debt Cost | 4.61% |
| Equity Weight | 60.14% |
| Equity Cost | 6.80% |
| WACC | 5.92% |
| Leverage | 66.29% |
Innoviva, Inc. : Quality Control
Innoviva, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MEIP | MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta … |
| CPRX | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, … |
| HRTX | Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
| SPRO | Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Innoviva
A-Score
1-Year Total Return ->
🥈
Catalyst Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
MEI Pharma
A-Score
1-Year Total Return ->
4
Spero Therapeutics
A-Score
1-Year Total Return ->
5
Heron Therapeutics
A-Score
1-Year Total Return ->
6
